Biogen Idec's Commitment To MS Demonstrated Through Significant Scientific ... TheStreet.com (press release) ... include analyses of pooled data from the Phase 3 DEFINE and CONFIRM clinical trials of oral dimethyl fumarate (BG-12), primary results from the daclizumab high-yield process (DAC HYP) SELECTION study, and early-stage research showing the results of ... |
